SARAH, 43
Sarah sought treatment for IDA to address her symptoms of fatigue
PATIENT PROFILES
DO THESE PROFILES RESEMBLE YOUR IDA PATIENT POPULATION?* IF SO, TREATMENT WITH MONOFERRIC MAY BE CONSIDERED.
JIM, 50
1 infusion kept Jim's calendar open
NEIL, 67
Neil needed his iron replenished after surgery
SHANNON, 38
Shannon manages IDA with just 1 dose at a time
Sarah experiences iron deficiency anemia due to her inflammatory bowel disease
WHY MONOFERRIC WAS RIGHT FOR SARAH
- Works long hours and has three young children
- Busy schedule often makes it hard for her to prioritize treatment
- Wants the convenience of a single infusion
- She experienced an unsatisfactory response to oral iron
Would any of your patients benefit from only 1 Monoferric infusion?
SEE THE EFFICACY DATA FOR SINGLE-DOSE MONOFERRIC
REVIEW THE RESULTS
Jim was diagnosed with iron deficiency anemia due to his colon cancer
WHY MONOFERRIC WAS RIGHT FOR JIM
- Has a history of oral iron intolerance and is waiting for surgery in the near future
- Loves the freedom of being a freelance photographer and creating his own schedule
- Lives in a rural community without close access to an infusion center
- Due to the long distance, he preferred to only travel for 1 infusion
Could your long-distance patients benefit from just 1 Monoferric infusion?
LEARN MORE ABOUT 1-DOSE ADMINISTRATION
SEE DOSING & ADMINISTRATION
Neil experienced iron deficiency anemia after his bariatric surgery
WHY MONOFERRIC WAS RIGHT FOR NEIL
- On Medicare and made the decision to undergo bariatric surgery
- Developed iron deficiency anemia post-surgery
- Experienced an unsatisfactory response to oral iron
- Neil's healthcare provider worked with Monoferric Patient Solutions® to address coverage concerns
Would any of your IDA Medicare patients prefer 1 dose of Monoferric?
DISCOVER THE MONOFERRIC PATIENT SOLUTIONS® PROGRAM
SEE HOW WE CAN HELP
Shannon experienced iron deficiency anemia due to her heavy menstrual bleeding
WHY MONOFERRIC WAS RIGHT FOR SHANNON
- Had an unsatisfactory response to oral iron
- Developed low phosphate levels with IV iron treatment prior to Monoferric
- As an architect, she is always on her feet
- Appreciates being efficient with one dose to help her manage her IDA fatigue
Have you considered how your repeat IDA patients may benefit from 1 Monoferric infusion?
REVIEW THE HEAD-TO-HEAD CLINICAL TRIAL DATA
SEE THE RESULTS
*All images are for illustration purposes only. The adults shown in the photos are not real patients. Monoferric is not indicated for children.
HAVE A QUESTION ABOUT HOW MONOFERRIC WORKS?
Sign up to contact a representative and receive information about Monoferric.
CONNECT WITH US
INDICATIONS
Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:
- who have intolerance to oral iron or have had unsatisfactory response to oral iron
- who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components. In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.
Iron Overload
Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferric to patients with iron overload.
ADVERSE REACTIONS
Adverse reactions were reported in 8.6% (172/2008) of patients treated with Monoferric. Adverse reactions related to treatment and reported by ≥1% of the treated patients were nausea (1.2%) and rash (1%). Adjudicated serious or severe hypersensitivity reactions were reported in 6/2008 (0.3%) patients in the Monoferric group. Hypophosphatemia (serum phosphate <2.0 mg/dL) was reported in 3.5% of Monoferric-treated patients in Trials 1 & 2.
To report adverse events, please contact Pharmacosmos at 1-888-828-0655. You may also contact the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.
